Participants were randomly assigned either to escalation of dulaglutide to 4.5 mg or maximum tolerated dose (MTD), or to ...

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide (Mounjaro) rather than increasing the dose of the earlier-generation ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide. (HealthDay News) — For patients with inadequately controlled type 2 diabetes ...

Nimacimab alone demonstrated 23.5% weight loss, comparable to monlunabant and tirzepatide alone. “This new preclinical study highlights that a truly peripherally-restricted CB1 inhibitor ...

Once-weekly treatment with tirzepatide can produce clinically meaningful ... and the longest time to weight plateau (see figure in notes to editors). As Dr Busetto explains: “Adults in Group ...

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both ...

This post hoc analysis of the SURMOUNT-1 study, at 3 years, aimed to assess weight regain from nadir weight over 3 years (36 months / 176 weeks) with tirzepatide treatment. The original SURMOUNT-1 ...